Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 14/20 | 0.74 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6020357 | 0.91 | ECE1 (0.73) | ECE1KDM1ARCOR1LMNAALDH1A1 | |
| SCHEMBL6175193 | 0.86 | ECE1 (0.58) | ECE1LMNAALDH1A1HTT | |
| SCHEMBL8338350 | 0.85 | ECE1 (0.55) | ECE1KDM1ARCOR1ALDH1A1TSHR | |
| SCHEMBL8337114 | 0.85 | ECE1 (1.00) | ECE1 | |
| SCHEMBL8334700 | 0.85 | ECE1 (0.85) | ECE1 | |
| SCHEMBL8362934 | 0.78 | ECE1 (0.81) | ECE1 | |
| SCHEMBL8337177 | 0.73 | KDM1A (0.60) | ECE1KDM1ARCOR1ALDH1A1TSHR | |
| SCHEMBL6018635 | 0.70 | KDM1A (0.56) | ECE1KDM1ARCOR1LMNAALDH1A1 | |
| SCHEMBL6020433 | 0.70 | ECE1 (0.81) | ECE1 | |
| SCHEMBL11732481 | 0.69 | LMNA (0.59) | ECE1LMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | BAYER HEALTHCARE AG (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7045544-B2 | Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2006-05-16 | — | — | US | disclosed |
| EP-1578418-A2 | USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES | Bayer HealthCare AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004056768-A2 | USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | DCK, UROD, QDPR | ECE1 756/4885KDM1A 2932/4885RCOR1 2039/4885 |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | ECE1, ECE2, EDNRA | ECE1 1/4885KDM1A 635/4885RCOR1 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.